Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage ...
Synaptic plasticity—the brain's ability to modify the connections between neurons to support learning—is one of the neural ...
BioNTech stock is a "Strong Buy", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read ...
Photon Design, a global leader in photonic simulation CAD software, enables rigorous 3D simulations of entire, Thin Film ...
Abstract: Modern RF communication and electronic warfare applications require systems capable of amplifying signals with high bandwidths and high peak-to-average power ratios (PAPRs). One technique ...
Background CFTR modulators have transformed cystic fibrosis (CF) treatment, but individual responses vary even among patients with identical CFTR genotypes. This underscores the need for predictive ...
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first ...
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the ...
Q3 2025 Earnings Call Transcript December 4, 2025 Operator: Good day, and thank you for standing by. Welcome to the Addex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback